Skip to main content
Evidence Snapshot

Testis-specific serine/threonine-protein kinase 1

CHEMBL6003 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL6003
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Testis-specific serine/threonine-protein kinase 1 as ChEMBL target CHEMBL6003, mapped to UniProt Q9BXA7. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Testis-specific serine/threonine-protein kinase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL6003
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9BXA7
Testis-specific serine/threonine-protein kinase 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Testis-specific serine/threonine-protein kinase 1 matters

As of 2026-09-13

Testis-specific serine/threonine-protein kinase 1 is reviewed as Testis-specific serine/threonine-protein kinase 1 (UniProt Q9BXA7); the current evidence base includes 7 approved drugs, 1473 compounds, and 272 assays, with lead potency reaching pChEMBL 10.3.

Protein context
Testis-specific serine/threonine-protein kinase 1

Testis-specific serine/threonine-protein kinase 1 Sequence length is 367 aa.

Review this target as Testis-specific serine/threonine-protein kinase 1, mapped to UniProt Q9BXA7. Sequence length is 367 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt Q9BXA7 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 7 approved drugs, 1473 compounds, and 272 assays for this target. The dominant activity type is KI. CHEMBL388978 is the current potency anchor at pChEMBL 10.3.

Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 10.3).

Activity source · ChEMBL 36 via Core Engine
7 approved pChEMBL 10.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Testis-specific serine/threonine-protein kinase 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9BXA7, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1473
Total Compounds
272
Total Assays
7
Approved Drugs
IC50: 35.0, KI: 515.0, KD: 123.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL388978
 10.3 IC50 —
No preferred name
CHEMBL4546504
 9.7 IC50 —
No preferred name
CHEMBL1971029
 8.6 Ki —
No preferred name
CHEMBL3545311
 8.4 IC50 Approved
No preferred name
CHEMBL2001751
 8.2 Ki —

Approved Drugs

Structure Compound First Approval
BRIGATINIB
CHEMBL3545311
 2017
CERITINIB
CHEMBL2403108
 2014
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL6003